Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POCUS: Hemostatic Potential and Joint Health in Severe Hemophilia A
NCT04690322Phase 4Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Apr 2021
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of eftrenonacog alfa, recombinant coagulation factor viii, emicizumab in hemophilia A, sponsored by UT Southwestern Medical Center. Planned start Apr 2021; status: withdrawn.
02
Drugs
eftrenonacog alfarecombinant coagulation factor viiiemicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04690322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04690322.